However, among the various biological therapies approved for RA, those targeting TNF-α and IL-6 are of particular interest in the context of mental health outcomes, including neuroinflammatory and neuroendocrine alterations [21,22]. The gene discussed is IL6; the disease is rheumatoid arthritis.